Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
8.72
Dollar change
+0.01
Percentage change
0.11
%
IndexRUT P/E- EPS (ttm)-1.79 Insider Own7.30% Shs Outstand70.12M Perf Week-4.39%
Market Cap621.56M Forward P/E- EPS next Y-0.78 Insider Trans-0.77% Shs Float66.07M Perf Month7.52%
Income-125.97M PEG- EPS next Q-0.42 Inst Own95.34% Short Float6.11% Perf Quarter-29.51%
Sales50.46M P/S12.32 EPS this Y28.48% Inst Trans-0.52% Short Ratio6.34 Perf Half Y4.56%
Book/sh6.15 P/B1.42 EPS next Y36.42% ROA-21.82% Short Interest4.03M Perf Year-0.91%
Cash/sh4.84 P/C1.80 EPS next 5Y11.00% ROE-27.64% 52W Range6.01 - 13.14 Perf YTD-16.07%
Dividend Est.- P/FCF- EPS past 5Y-6.52% ROI-27.44% 52W High-33.64% Beta1.19
Dividend TTM- Quick Ratio6.92 Sales past 5Y264.10% Gross Margin66.87% 52W Low44.97% ATR (14)0.42
Dividend Ex-Date- Current Ratio6.92 EPS Y/Y TTM-168.88% Oper. Margin-294.42% RSI (14)42.90 Volatility3.39% 5.10%
Employees277 Debt/Eq0.06 Sales Y/Y TTM-88.69% Profit Margin-249.63% Recom1.75 Target Price13.53
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q-14.52% Payout- Rel Volume0.49 Prev Close8.71
Sales Surprise-42.74% EPS Surprise-30.43% Sales Q/Q-71.81% EarningsMay 02 AMC Avg Volume636.23K Price8.72
SMA20-2.53% SMA50-6.92% SMA200-2.82% Trades Volume310,059 Change0.11%
Date Action Analyst Rating Change Price Target Change
Mar-21-23Resumed Wells Fargo Overweight $12
Jan-04-23Reiterated H.C. Wainwright Neutral $10 → $8
Dec-20-22Upgrade Jefferies Hold → Buy $7.70 → $11
Nov-01-22Downgrade H.C. Wainwright Buy → Neutral $40 → $8
Oct-21-22Downgrade SVB Leerink Outperform → Mkt Perform $8
Oct-04-22Resumed Wells Fargo Overweight $45 → $9
May-05-22Upgrade Guggenheim Neutral → Buy $14
Mar-15-22Initiated Evercore ISI Outperform $15
Dec-10-21Upgrade SVB Leerink Mkt Perform → Outperform
Nov-17-21Resumed Guggenheim Neutral
May-19-24 09:00PM
May-16-24 04:20PM
May-02-24 04:05PM
Apr-30-24 06:00AM
Apr-11-24 06:00AM
09:35AM Loading…
Apr-10-24 09:35AM
Apr-08-24 06:00AM
Mar-28-24 06:00AM
Mar-27-24 06:00AM
Mar-22-24 12:00PM
Mar-11-24 12:44PM
Mar-09-24 01:09PM
Mar-07-24 06:39AM
Mar-06-24 10:53PM
04:09PM
04:30PM Loading…
Mar-05-24 04:30PM
Feb-28-24 10:00AM
Feb-27-24 06:00AM
Feb-14-24 06:00AM
Feb-09-24 08:00AM
Feb-08-24 06:00AM
Jan-31-24 06:00AM
Jan-11-24 12:00PM
Jan-04-24 06:15AM
06:00AM
Dec-26-23 08:00AM
Dec-15-23 08:30AM
Dec-08-23 10:11AM
Nov-30-23 08:30AM
Nov-08-23 05:33PM
04:05PM Loading…
Nov-07-23 04:05PM
Nov-01-23 08:30AM
Oct-17-23 08:30AM
Oct-16-23 04:30PM
Aug-10-23 04:05PM
Aug-01-23 08:30AM
Jul-19-23 08:30AM
Jul-03-23 08:30AM
Jun-29-23 04:05PM
Jun-26-23 08:30AM
Jun-02-23 06:41PM
Jun-01-23 08:30AM
May-18-23 08:30AM
May-08-23 04:05PM
May-01-23 08:30AM
Apr-18-23 04:05PM
Apr-17-23 08:30AM
Apr-10-23 08:30AM
Apr-03-23 08:30AM
Mar-14-23 04:30PM
Mar-07-23 04:05PM
Feb-28-23 08:30AM
Feb-21-23 08:30AM
Jan-25-23 08:30AM
Jan-19-23 07:45AM
Jan-04-23 04:15PM
Dec-21-22 07:30AM
07:30AM
Dec-19-22 07:00AM
Dec-14-22 04:15PM
Dec-09-22 08:00AM
Dec-05-22 08:30AM
Nov-29-22 08:30AM
Nov-24-22 12:20PM
Nov-22-22 09:55AM
08:30AM
Nov-21-22 12:22PM
09:55AM
09:00AM
Nov-08-22 05:45PM
04:22PM
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-31-22 04:42PM
Oct-21-22 01:35PM
Oct-20-22 01:36PM
11:48AM
08:30AM
Oct-19-22 11:08AM
08:38AM
07:29AM
06:07AM
06:00AM
Oct-18-22 08:30AM
Oct-13-22 07:00AM
Oct-07-22 04:15PM
Oct-04-22 08:30AM
Oct-03-22 08:30AM
Sep-29-22 07:30AM
Sep-26-22 04:15PM
Sep-16-22 08:30AM
Sep-13-22 09:34AM
Sep-08-22 04:15PM
Sep-04-22 06:05PM
Aug-04-22 08:35PM
04:15PM
Aug-01-22 08:30AM
Jul-27-22 08:45AM
Jul-25-22 08:30AM
Jul-22-22 08:30AM
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Galbraith KennethChair & CEOJan 08 '24Sale11.225,70663,99623,762Jan 08 06:23 PM
Moore Paul AndrewChief Scientific OfficerJan 08 '24Sale11.222,33926,2337,367Jan 08 06:01 PM
Astle ChristopherSVP & Chief Financial OfficerJan 08 '24Sale11.221,43116,0506,503Jan 08 06:14 PM
Moore Paul AndrewChief Scientific OfficerJan 05 '24Option Exercise0.0017,166017,166Jan 08 06:01 PM
Galbraith KennethChair & CEOJan 05 '24Option Exercise0.0047,666047,666Jan 08 06:23 PM
Astle ChristopherSVP & Chief Financial OfficerJan 05 '24Option Exercise0.0010,500012,497Jan 08 06:14 PM
Galbraith KennethChair & CEOJan 05 '24Sale10.6518,198193,84929,468Jan 08 06:23 PM
Moore Paul AndrewChief Scientific OfficerJan 05 '24Sale10.657,46079,4659,706Jan 08 06:01 PM
Astle ChristopherSVP & Chief Financial OfficerJan 05 '24Sale10.654,56348,6067,934Jan 08 06:14 PM
Astle ChristopherSVP & Chief Financial OfficerDec 11 '23Option Exercise0.001,55002,883Dec 11 08:00 PM
Astle ChristopherSVP & Chief Financial OfficerDec 11 '23Sale9.138868,0891,997Dec 11 08:00 PM
EcoR1 Capital, LLC10% OwnerJun 16 '23Buy8.123,350,00027,202,00013,437,473Jun 21 04:04 PM